Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial
暂无分享,去创建一个
Lidia Ruiz | Cristian Tebé | Jordi Puig | Oriol Mitjà | Bonaventura Clotet | C. Tebé | B. Clotet | L. Ruiz | M. Farré | E. Ballana | A. Elizalde-Torrent | A. Tobías | G. Flores-Mateo | J. Puig | J. Ara | Eva Riveira-Muñoz | O. Mitjà | J. Casabona | Jordi Casabona | J. Argimón | Laia Bertran | Gemma Flores-Mateo | R. Vivanco-Hidalgo | Eva Riveira-Muñoz | Ester Ballana | Aroa Nieto | Marc Corbacho-Monné | Maria Ubals | Judith Peñafiel | Aurelio Tobias | Andrea Alemany | Núria Riera-Martí | Carla A Pérez | Clara Suñer | Pep Laporte | Pol Admella | Jordi Mitjà | Mireia Clua | Laia Bertran | Maria Sarquella | Sergi Gavilán | Jordi Ara | Josep M Argimon | Gabriel Cuatrecasas | Paz Cañadas | Aleix Elizalde-Torrent | Robert Fabregat | Magí Farré | Anna Forcada | Esteve Muntada | Núria Nadal | Silvia Narejos | Nuria Prat | Carles Quiñones | Juliana Reyes-Ureña | Ferran Ramírez-Viaplana | Alba Sierra | César Velasco | Rosa Maria Vivanco-Hidalgo | Alexis Sentís | Camila G-Beiras | Martí Vall-Mayans | J. Peñafiel | N. Nadal | N. Prat | A. Sierra | G. Cuatrecasas | C. Velasco | Maria Ubals | Clara Suñer | Robert Fabregat | S. Narejos | Sergi Gavilán | M. Vall-Mayans | A. Sentís | A. Alemany | M. Corbacho-Monné | Camila G-Beiras | Carles Quiñones | A. Nieto | Ferran Ramírez-Viaplana | Juliana Reyes-Ureña | A. Forcada | E. Muntada | N. Riera-Martí | Maria Sarquella | C. A. Pérez | Pol Admella | P. Laporte | J. Mitjà | M. Clua | P. Cañadas | C. Quiñones | E. Riveira-Muñoz | L. Ruíz | Núria Nadal
[1] Runnan Shen,et al. Molecular Modeling Evaluation of the Binding Abilities of Ritonavir and Lopinavir to Wuhan Pneumonia Coronavirus Proteases , 2020 .
[2] Mike Clarke,et al. A minimal common outcome measure set for COVID-19 clinical research , 2020, The Lancet Infectious Diseases.
[3] Alexis Jacquier,et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study , 2020, Travel Medicine and Infectious Disease.
[4] Zhan Zhang,et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial , 2020, medRxiv.
[5] Jiang Liu,et al. Connecting hydroxychloroquine in vitro antiviral activity to in vivo concentration for prediction of antiviral effect: a critical step in treating COVID-19 patients , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[6] Madeeha Kamal,et al. Therapeutic management of patients with COVID-19: a systematic review , 2020, Infection Prevention in Practice.
[7] J. Margolick,et al. Estimating the benefit of an HIV-1 vaccine that reduces viral load set point. , 2007, The Journal of infectious diseases.
[8] G. Hripcsak,et al. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19 , 2020, The New England journal of medicine.
[9] D. Raoult,et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial , 2020, International Journal of Antimicrobial Agents.
[10] Jianjun Gao,et al. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. , 2020, Bioscience trends.
[11] J. Qu,et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial , 2020, BMJ.
[12] Yuan Wei,et al. A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 , 2020, The New England journal of medicine.
[13] Madeeha Kamal,et al. Therapeutic management of patients with COVID-19: a systematic review , 2020, Infection Prevention in Practice.
[14] C. Delaugerre,et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection , 2020, Médecine et Maladies Infectieuses.
[15] Roberto Cauda,et al. New insights into the antiviral effects of chloroquine , 2006, The Lancet Infectious Diseases.
[16] I. Ben-Zvi,et al. Hydroxychloroquine: From Malaria to Autoimmunity , 2011, Clinical Reviews in Allergy & Immunology.
[17] O. Tsang,et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study , 2020, The Lancet Infectious Diseases.
[18] P. Zimetbaum,et al. Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19). , 2020, JAMA cardiology.
[19] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[20] Jianjun Gao,et al. Discovering drugs to treat coronavirus disease 2019 (COVID-19). , 2020, Drug discoveries & therapeutics.
[21] David R. Holtgrave,et al. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State , 2020, The Journal of Emergency Medicine.
[22] Xu Liu,et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[23] Wu Zhong,et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro , 2020, Cell Research.
[24] Denisa Bojkova,et al. Lack of antiviral activity of darunavir against SARS-CoV-2 , 2020, International Journal of Infectious Diseases.
[25] Denisa Bojkova,et al. Lack of antiviral activity of darunavir against SARS-CoV-2 , 2020, International Journal of Infectious Diseases.